Global Oncolytic Virus Therapy Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
According to APO Research, The global Oncolytic Virus Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
This report presents an overview of global market for Oncolytic Virus Therapy, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncolytic Virus Therapy, also provides the value of main regions and countries. Of the upcoming market potential for Oncolytic Virus Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncolytic Virus Therapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Oncolytic Virus Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global @@@@ company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Descriptive company profiles of the major global players, including Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics and Sorrento Therapeutics, etc.
Oncolytic Virus Therapy segment by Company
1. To analyze and research the global Oncolytic Virus Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Oncolytic Virus Therapy key companies, revenue, market share, and recent developments.
3. To split the Oncolytic Virus Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Oncolytic Virus Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oncolytic Virus Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Oncolytic Virus Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncolytic Virus Therapy industry.
Chapter 3: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Oncolytic Virus Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Chapter 9: Concluding Insights.
According to APO Research, The global Oncolytic Virus Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
This report presents an overview of global market for Oncolytic Virus Therapy, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncolytic Virus Therapy, also provides the value of main regions and countries. Of the upcoming market potential for Oncolytic Virus Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncolytic Virus Therapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Oncolytic Virus Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global @@@@ company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Descriptive company profiles of the major global players, including Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics and Sorrento Therapeutics, etc.
Oncolytic Virus Therapy segment by Company
- Amgen
- Oncolytics Biotech
- Viralytics
- Transgene SA
- Oncolys BioPharma
- Targovax
- PsiOxus Therapeutics
- SillaJen Biotherapeutics
- Sorrento Therapeutics
- Lokon Pharma
- Genelux Corporation
- Vyriad
- TILT Biotherapeutics
- Cold Genesys
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Oncolytic Virus Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Oncolytic Virus Therapy key companies, revenue, market share, and recent developments.
3. To split the Oncolytic Virus Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Oncolytic Virus Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Oncolytic Virus Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Oncolytic Virus Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncolytic Virus Therapy industry.
Chapter 3: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Oncolytic Virus Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Oncolytic Virus Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Oncolytic Virus Therapy Market Size, 2019 VS 2023 VS 2030
1.3 Global Oncolytic Virus Therapy Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
2.1 Oncolytic Virus Therapy Industry Trends
2.2 Oncolytic Virus Therapy Industry Drivers
2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
2.4 Oncolytic Virus Therapy Industry Restraints
3 ONCOLYTIC VIRUS THERAPY MARKET BY COMPANY
3.1 Global Oncolytic Virus Therapy Company Revenue Ranking in 2023
3.2 Global Oncolytic Virus Therapy Revenue by Company (2019-2024)
3.3 Global Oncolytic Virus Therapy Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Oncolytic Virus Therapy Company Manufacturing Base & Headquarters
3.5 Global Oncolytic Virus Therapy Company, Product Type & Application
3.6 Global Oncolytic Virus Therapy Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Oncolytic Virus Therapy Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 ONCOLYTIC VIRUS THERAPY MARKET BY TYPE
4.1 Oncolytic Virus Therapy Type Introduction
4.1.1 HSV-based Oncolytic Viruses
4.1.2 Adenoviruses-based Oncolytic Viruses
4.1.3 Vaccinia Virus-based Oncolytic Viruses
4.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.1.5 Newcastle Disease Virus-based Oncolytic Viruses
4.2 Global Oncolytic Virus Therapy Sales Value by Type
4.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Oncolytic Virus Therapy Sales Value by Type (2019-2030)
4.2.3 Global Oncolytic Virus Therapy Sales Value Share by Type (2019-2030)
5 ONCOLYTIC VIRUS THERAPY MARKET BY APPLICATION
5.1 Oncolytic Virus Therapy Application Introduction
5.1.1 Melanoma
5.1.2 Prostate Cancer
5.1.3 Breast Cancer
5.1.4 Ovarian Cancer
5.1.5 Others
5.2 Global Oncolytic Virus Therapy Sales Value by Application
5.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Oncolytic Virus Therapy Sales Value by Application (2019-2030)
5.2.3 Global Oncolytic Virus Therapy Sales Value Share by Application (2019-2030)
6 ONCOLYTIC VIRUS THERAPY MARKET BY REGION
6.1 Global Oncolytic Virus Therapy Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Oncolytic Virus Therapy Sales Value by Region (2019-2030)
6.2.1 Global Oncolytic Virus Therapy Sales Value by Region: 2019-2024
6.2.2 Global Oncolytic Virus Therapy Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Oncolytic Virus Therapy Sales Value (2019-2030)
6.3.2 North America Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oncolytic Virus Therapy Sales Value (2019-2030)
6.4.2 Europe Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Oncolytic Virus Therapy Sales Value (2019-2030)
6.5.2 Asia-Pacific Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Oncolytic Virus Therapy Sales Value (2019-2030)
6.6.2 Latin America Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Oncolytic Virus Therapy Sales Value (2019-2030)
6.7.2 Middle East & Africa Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
7 ONCOLYTIC VIRUS THERAPY MARKET BY COUNTRY
7.1 Global Oncolytic Virus Therapy Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Oncolytic Virus Therapy Sales Value by Country (2019-2030)
7.2.1 Global Oncolytic Virus Therapy Sales Value by Country (2019-2024)
7.2.2 Global Oncolytic Virus Therapy Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.3.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.4.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.5.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.6.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.7.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.8.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.9.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.10.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.11.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.12.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.13.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.14.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.15.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.16.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.17.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.18.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.19.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.20.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.21.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Amgen
8.1.1 Amgen Comapny Information
8.1.2 Amgen Business Overview
8.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
8.1.5 Amgen Recent Developments
8.2 Oncolytics Biotech
8.2.1 Oncolytics Biotech Comapny Information
8.2.2 Oncolytics Biotech Business Overview
8.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
8.2.5 Oncolytics Biotech Recent Developments
8.3 Viralytics
8.3.1 Viralytics Comapny Information
8.3.2 Viralytics Business Overview
8.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
8.3.5 Viralytics Recent Developments
8.4 Transgene SA
8.4.1 Transgene SA Comapny Information
8.4.2 Transgene SA Business Overview
8.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
8.4.5 Transgene SA Recent Developments
8.5 Oncolys BioPharma
8.5.1 Oncolys BioPharma Comapny Information
8.5.2 Oncolys BioPharma Business Overview
8.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
8.5.5 Oncolys BioPharma Recent Developments
8.6 Targovax
8.6.1 Targovax Comapny Information
8.6.2 Targovax Business Overview
8.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
8.6.5 Targovax Recent Developments
8.7 PsiOxus Therapeutics
8.7.1 PsiOxus Therapeutics Comapny Information
8.7.2 PsiOxus Therapeutics Business Overview
8.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
8.7.5 PsiOxus Therapeutics Recent Developments
8.8 SillaJen Biotherapeutics
8.8.1 SillaJen Biotherapeutics Comapny Information
8.8.2 SillaJen Biotherapeutics Business Overview
8.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
8.8.5 SillaJen Biotherapeutics Recent Developments
8.9 Sorrento Therapeutics
8.9.1 Sorrento Therapeutics Comapny Information
8.9.2 Sorrento Therapeutics Business Overview
8.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
8.9.5 Sorrento Therapeutics Recent Developments
8.10 Lokon Pharma
8.10.1 Lokon Pharma Comapny Information
8.10.2 Lokon Pharma Business Overview
8.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
8.10.5 Lokon Pharma Recent Developments
8.11 Genelux Corporation
8.11.1 Genelux Corporation Comapny Information
8.11.2 Genelux Corporation Business Overview
8.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
8.11.5 Genelux Corporation Recent Developments
8.12 Vyriad
8.12.1 Vyriad Comapny Information
8.12.2 Vyriad Business Overview
8.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
8.12.5 Vyriad Recent Developments
8.13 TILT Biotherapeutics
8.13.1 TILT Biotherapeutics Comapny Information
8.13.2 TILT Biotherapeutics Business Overview
8.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
8.13.5 TILT Biotherapeutics Recent Developments
8.14 Cold Genesys
8.14.1 Cold Genesys Comapny Information
8.14.2 Cold Genesys Business Overview
8.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
8.14.5 Cold Genesys Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
10.6 Disclaimer
1.1 Product Definition
1.2 Global Oncolytic Virus Therapy Market Size, 2019 VS 2023 VS 2030
1.3 Global Oncolytic Virus Therapy Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 ONCOLYTIC VIRUS THERAPY MARKET DYNAMICS
2.1 Oncolytic Virus Therapy Industry Trends
2.2 Oncolytic Virus Therapy Industry Drivers
2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
2.4 Oncolytic Virus Therapy Industry Restraints
3 ONCOLYTIC VIRUS THERAPY MARKET BY COMPANY
3.1 Global Oncolytic Virus Therapy Company Revenue Ranking in 2023
3.2 Global Oncolytic Virus Therapy Revenue by Company (2019-2024)
3.3 Global Oncolytic Virus Therapy Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Oncolytic Virus Therapy Company Manufacturing Base & Headquarters
3.5 Global Oncolytic Virus Therapy Company, Product Type & Application
3.6 Global Oncolytic Virus Therapy Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Oncolytic Virus Therapy Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 ONCOLYTIC VIRUS THERAPY MARKET BY TYPE
4.1 Oncolytic Virus Therapy Type Introduction
4.1.1 HSV-based Oncolytic Viruses
4.1.2 Adenoviruses-based Oncolytic Viruses
4.1.3 Vaccinia Virus-based Oncolytic Viruses
4.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.1.5 Newcastle Disease Virus-based Oncolytic Viruses
4.2 Global Oncolytic Virus Therapy Sales Value by Type
4.2.1 Global Oncolytic Virus Therapy Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Oncolytic Virus Therapy Sales Value by Type (2019-2030)
4.2.3 Global Oncolytic Virus Therapy Sales Value Share by Type (2019-2030)
5 ONCOLYTIC VIRUS THERAPY MARKET BY APPLICATION
5.1 Oncolytic Virus Therapy Application Introduction
5.1.1 Melanoma
5.1.2 Prostate Cancer
5.1.3 Breast Cancer
5.1.4 Ovarian Cancer
5.1.5 Others
5.2 Global Oncolytic Virus Therapy Sales Value by Application
5.2.1 Global Oncolytic Virus Therapy Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Oncolytic Virus Therapy Sales Value by Application (2019-2030)
5.2.3 Global Oncolytic Virus Therapy Sales Value Share by Application (2019-2030)
6 ONCOLYTIC VIRUS THERAPY MARKET BY REGION
6.1 Global Oncolytic Virus Therapy Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Oncolytic Virus Therapy Sales Value by Region (2019-2030)
6.2.1 Global Oncolytic Virus Therapy Sales Value by Region: 2019-2024
6.2.2 Global Oncolytic Virus Therapy Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Oncolytic Virus Therapy Sales Value (2019-2030)
6.3.2 North America Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oncolytic Virus Therapy Sales Value (2019-2030)
6.4.2 Europe Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Oncolytic Virus Therapy Sales Value (2019-2030)
6.5.2 Asia-Pacific Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Oncolytic Virus Therapy Sales Value (2019-2030)
6.6.2 Latin America Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Oncolytic Virus Therapy Sales Value (2019-2030)
6.7.2 Middle East & Africa Oncolytic Virus Therapy Sales Value Share by Country, 2023 VS 2030
7 ONCOLYTIC VIRUS THERAPY MARKET BY COUNTRY
7.1 Global Oncolytic Virus Therapy Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Oncolytic Virus Therapy Sales Value by Country (2019-2030)
7.2.1 Global Oncolytic Virus Therapy Sales Value by Country (2019-2024)
7.2.2 Global Oncolytic Virus Therapy Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.3.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.4.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.5.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.6.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.7.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.8.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.9.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.10.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.11.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.12.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.13.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.14.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.15.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.16.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.17.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.18.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.19.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.20.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Oncolytic Virus Therapy Sales Value Growth Rate (2019-2030)
7.21.2 Global Oncolytic Virus Therapy Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Oncolytic Virus Therapy Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Amgen
8.1.1 Amgen Comapny Information
8.1.2 Amgen Business Overview
8.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
8.1.5 Amgen Recent Developments
8.2 Oncolytics Biotech
8.2.1 Oncolytics Biotech Comapny Information
8.2.2 Oncolytics Biotech Business Overview
8.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
8.2.5 Oncolytics Biotech Recent Developments
8.3 Viralytics
8.3.1 Viralytics Comapny Information
8.3.2 Viralytics Business Overview
8.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
8.3.5 Viralytics Recent Developments
8.4 Transgene SA
8.4.1 Transgene SA Comapny Information
8.4.2 Transgene SA Business Overview
8.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
8.4.5 Transgene SA Recent Developments
8.5 Oncolys BioPharma
8.5.1 Oncolys BioPharma Comapny Information
8.5.2 Oncolys BioPharma Business Overview
8.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
8.5.5 Oncolys BioPharma Recent Developments
8.6 Targovax
8.6.1 Targovax Comapny Information
8.6.2 Targovax Business Overview
8.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
8.6.5 Targovax Recent Developments
8.7 PsiOxus Therapeutics
8.7.1 PsiOxus Therapeutics Comapny Information
8.7.2 PsiOxus Therapeutics Business Overview
8.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
8.7.5 PsiOxus Therapeutics Recent Developments
8.8 SillaJen Biotherapeutics
8.8.1 SillaJen Biotherapeutics Comapny Information
8.8.2 SillaJen Biotherapeutics Business Overview
8.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
8.8.5 SillaJen Biotherapeutics Recent Developments
8.9 Sorrento Therapeutics
8.9.1 Sorrento Therapeutics Comapny Information
8.9.2 Sorrento Therapeutics Business Overview
8.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
8.9.5 Sorrento Therapeutics Recent Developments
8.10 Lokon Pharma
8.10.1 Lokon Pharma Comapny Information
8.10.2 Lokon Pharma Business Overview
8.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
8.10.5 Lokon Pharma Recent Developments
8.11 Genelux Corporation
8.11.1 Genelux Corporation Comapny Information
8.11.2 Genelux Corporation Business Overview
8.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
8.11.5 Genelux Corporation Recent Developments
8.12 Vyriad
8.12.1 Vyriad Comapny Information
8.12.2 Vyriad Business Overview
8.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
8.12.5 Vyriad Recent Developments
8.13 TILT Biotherapeutics
8.13.1 TILT Biotherapeutics Comapny Information
8.13.2 TILT Biotherapeutics Business Overview
8.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
8.13.5 TILT Biotherapeutics Recent Developments
8.14 Cold Genesys
8.14.1 Cold Genesys Comapny Information
8.14.2 Cold Genesys Business Overview
8.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2019-2024)
8.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
8.14.5 Cold Genesys Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
10.6 Disclaimer
